Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting · NCT07163273 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Recruiting | Phase 2 | 2026-09-25 | NCT07163273 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Northwell Health | 107 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Imbert Cancer Center | Bay Shore | United States | 1 |
| Long Island Jewish Medical Center | New Hyde Park | United States | 49 |
| Manhattan Eye, Ear and Throat Hospital | New York | United States | 2 |
| NHPP Medical Oncology at Rego Park | Rego Park | United States | 1 |
| Northern Westchester Cancer Center | Mount Kisco | United States | 1 |
| Phelps Cancer Center | Sleepy Hollow | United States | 1 |
| Zuckerberg Cancer Center | New Hyde Park | United States | 3 |